Qinghai Zhao, Ph.D., is the Chief Manufacturing Officer of Adagene. He has over 25 years of drug development experience in the biopharmaceutical industry.

Most recently, he served as the Vice President of Technical Development and Manufacturing at Forty Seven Inc., an immunology company acquired by Gilead in early 2020. There, he was responsible for CMC development and clinical supply management for a number of programs, including magrolimab. Prior to Forty Seven, Dr. Zhao was the Vice President of CMC and Manufacturing at AnaptysBio. Prior to that, he held leadership positions in managing biological process development and manufacturing, including Head of CMC at NGM Bio and Director of CMC management at Teva Biopharmaceuticals USA, where he led multiple CMC programs including reslizumab, which was approved by the FDA for commercial manufacturing in 2016. In his early career in China, he served as Head of Plasma Protein Therapeutics R/D at Shanghai Institute of Biological Products.

Dr. Zhao earned his Ph.D. in life sciences from Uppsala University, his MS in biochemistry from Fudan University (Shanghai Medical University) and BE degree in biochemistry from East China University of Science and Technology.